| # | Title | Journal | Year | Citations |
|---|
| 1 | Lung cancer: current therapies and new targeted treatments | Lancet, The | 2017 | 2,267 |
| 2 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 | Blood | 2013 | 1,743 |
| 3 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 1,571 |
| 4 | Liquid biopsy: monitoring cancer-genetics in the blood | Nature Reviews Clinical Oncology | 2013 | 1,482 |
| 5 | Integrating liquid biopsies into the management of cancer | Nature Reviews Clinical Oncology | 2017 | 1,375 |
| 6 | Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research | Cancer Discovery | 2014 | 1,341 |
| 7 | Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma | JAMA Oncology | 2016 | 1,192 |
| 8 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 842 |
| 9 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Lancet Oncology, The | 2014 | 823 |
| 10 | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients | Nature Medicine | 2015 | 809 |
| 11 | Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition | Nature Medicine | 2016 | 768 |
| 12 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2020 | 710 |
| 13 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma | Nature | 2014 | 702 |
| 14 | Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial | Lancet Oncology, The | 2016 | 689 |
| 15 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death | | 2020 | 610 |
| 16 | Toward understanding and exploiting tumor heterogeneity | Nature Medicine | 2015 | 604 |
| 17 | Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation | Lancet Oncology, The | 2020 | 588 |
| 18 | Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer | Cancer Discovery | 2013 | 585 |
| 19 | Interrogating open issues in cancer precision medicine with patient-derived xenografts | Nature Reviews Cancer | 2017 | 527 |
| 20 | Stromal contribution to the colorectal cancer transcriptome | Nature Genetics | 2015 | 520 |
| 21 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC | Journal of Thoracic Oncology | 2018 | 515 |
| 22 | The Dual Roles of NRF2 in Cancer | Trends in Molecular Medicine | 2016 | 508 |
| 23 | Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity | Cancer Cell | 2013 | 505 |
| 24 | Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth | Nature | 2017 | 480 |
| 25 | Consensus guidelines for the use and interpretation of angiogenesis assays | Angiogenesis | 2018 | 429 |
| 26 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 418 |
| 27 | Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution | Cancer Discovery | 2014 | 415 |
| 28 | Liquid Biopsies, What We Do Not Know (Yet) | Cancer Cell | 2017 | 395 |
| 29 | Overview of the 2022 WHO Classification of Thyroid Neoplasms | Endocrine Pathology | 2022 | 388 |
| 30 | Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma | Cancer Discovery | 2017 | 384 |
| 31 | An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer | Clinical Lung Cancer | 2014 | 377 |
| 32 | Early‐onset colorectal cancer in young individuals | Molecular Oncology | 2019 | 365 |
| 33 | Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document | Radiotherapy and Oncology | 2020 | 352 |
| 34 | Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death | Frontiers in Immunology | 2015 | 317 |
| 35 | Adaptive mutability of colorectal cancers in response to targeted therapies | Science | 2019 | 290 |
| 36 | ESTRO-ACROP guideline “target delineation of glioblastomas” | Radiotherapy and Oncology | 2016 | 286 |
| 37 | Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature | European Urology | 2015 | 274 |
| 38 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer | Journal of Thoracic Oncology | 2021 | 274 |
| 39 | Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3 | Cell Reports | 2014 | 266 |
| 40 | Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group | International Journal of Radiation Oncology Biology Physics | 2014 | 259 |
| 41 | The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets | Nature Communications | 2015 | 251 |
| 42 | Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial | Journal of Thoracic Oncology | 2021 | 251 |
| 43 | Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer | Annals of Oncology | 2014 | 246 |
| 44 | EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer | Cancer Discovery | 2020 | 245 |
| 45 | SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo | Nature Medicine | 2018 | 244 |
| 46 | Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Annals of Oncology | 2018 | 243 |
| 47 | Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study | Annals of Oncology | 2018 | 238 |
| 48 | A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee | Journal of Thoracic Oncology | 2020 | 234 |
| 49 | How liquid biopsies can change clinical practice in oncology | Annals of Oncology | 2019 | 231 |
| 50 | Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer | Science Translational Medicine | 2014 | 228 |
